A Case of Recurrent Anaplastic Thyroid Cancer Treated by Lenvatinib after Successful Long-term Multimodal Therapy

DOI Web Site Web Site 2 Citations 10 References
  • ONODA Naoyoshi
    Department of Surgical Oncology, Osaka City University Graduate School of Medicine
  • TOKUMOTO Mao
    Department of Surgical Oncology, Osaka City University Graduate School of Medicine
  • NODA Satoru
    Department of Surgical Oncology, Osaka City University Graduate School of Medicine
  • OHIRA Go
    Department of Surgical Oncology, Osaka City University Graduate School of Medicine
  • KASHIWAGI Shinichiro
    Department of Surgical Oncology, Osaka City University Graduate School of Medicine
  • HIRAKAWA Kosei
    Department of Surgical Oncology, Osaka City University Graduate School of Medicine

Bibliographic Information

Other Title
  • Lenvatinibを投与した治療抵抗性再発甲状腺未分化癌の1例
  • 症例 Lenvatinibを投与した治療抵抗性再発甲状腺未分化癌の1例
  • ショウレイ Lenvatinib オ トウヨ シタ チリョウ テイコウセイ サイハツ コウジョウセン ミブンカガン ノ 1レイ

Search this article

Description

Anaplastic thyroid cancer (ATC) is an extremely aggressive malignancy with dismal prognosis due to resistance to multimodal therapy. Here, we present a case of ATC treated by lenvatinib, a multikinase inhibitor. A 66-year-old Japanese woman was referred to our hospital for the treatment of recurrent ATC on her neck after chemotherapy, surgery, and radio-therapy. The tumor successfully shrank within a month after initiating treatment with lenvatinib. Treatment was interrupted twice for grade 3 hypertension and proteinuria. A rupture of the carotid artery was successfully treated by emergent surgery (ligation of the carotid artery) followed by stent insertion into the subclavian artery.

Journal

Citations (2)*help

See more

References(10)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top